What are the treatment guidelines for accelerated-phase chronic myelogenous leukemia (CML)?

Updated: May 23, 2021
  • Author: Emmanuel C Besa, MD; Chief Editor: Sara J Grethlein, MD, FACP  more...
  • Print

For accelerated-phase CML, all the guidelines recommend the following:

  • TKI (imatinib, nilotinib, dasatinib, bosutinib, ponatinib).

  • Choice of TKI is based on prior therapy and/or BCR-ABL kinase domain mutation status

  • Recommended doses of imatinib, nilotinib, and dasatinib are higher for accelerated phase than for chronic phase

  • If resistance and/or intolerance to two or more TKIs occurs, consider omacetaxine

  • Consider HSCT, based on treatment response and patient age

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!